FDA To Use Enforcement Discretion Regarding Changes To NDAs, ANDAs
This article was originally published in The Pink Sheet Daily
Executive Summary
Post-approval manufacturing changes made to comply with U.S. Pharmacopeia standards may be submitted in an annual report, an FDA guidance states. The agency plans to clarify the types of changes that can be submitted in an annual report instead of a supplemental filing in an upcoming guidance.